165 related articles for article (PubMed ID: 37215715)
1. Leucine-rich alpha-2 glycoprotein as a potential biomarker for large vessel vasculitides.
Umezawa N; Mizoguchi F; Maejima Y; Kimura N; Hasegawa H; Hosoya T; Fujimoto M; Kohsaka H; Naka T; Yasuda S
Front Med (Lausanne); 2023; 10():1153883. PubMed ID: 37215715
[TBL] [Abstract][Full Text] [Related]
2. Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease.
Shimoyama T; Yamamoto T; Yoshiyama S; Nishikawa R; Umegae S
Inflamm Bowel Dis; 2023 Sep; 29(9):1399-1408. PubMed ID: 36334015
[TBL] [Abstract][Full Text] [Related]
3. Significance of Serum Leucine-rich Alpha-2 Glycoprotein as a Diagnostic Marker in Pediatric Inflammatory Bowel Disease.
Yoshimura S; Okata Y; Ooi M; Horinouchi T; Iwabuchi S; Kameoka Y; Watanabe A; Kondo A; Uemura K; Tomioka Y; Samejima Y; Nakai Y; Nozu K; Kodama Y; Bitoh Y
Kobe J Med Sci; 2024 Jan; 69(4):E122-E128. PubMed ID: 38379274
[TBL] [Abstract][Full Text] [Related]
4. Leucine-rich α2 -glycoprotein as a potential biomarker for joint inflammation during anti-interleukin-6 biologic therapy in rheumatoid arthritis.
Fujimoto M; Serada S; Suzuki K; Nishikawa A; Ogata A; Nanki T; Hattori K; Kohsaka H; Miyasaka N; Takeuchi T; Naka T
Arthritis Rheumatol; 2015 May; 67(8):2056-60. PubMed ID: 25917892
[TBL] [Abstract][Full Text] [Related]
5. Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis.
Shinzaki S; Matsuoka K; Iijima H; Mizuno S; Serada S; Fujimoto M; Arai N; Koyama N; Morii E; Watanabe M; Hibi T; Kanai T; Takehara T; Naka T
J Crohns Colitis; 2017 Jan; 11(1):84-91. PubMed ID: 27466171
[TBL] [Abstract][Full Text] [Related]
6. Leucine-Rich Alpha-2 Glycoprotein in Monitoring Disease Activity and Intestinal Stenosis in Inflammatory Bowel Disease.
Yoshida T; Shimodaira Y; Fukuda S; Watanabe N; Koizumi S; Matsuhashi T; Onochi K; Iijima K
Tohoku J Exp Med; 2022 Jul; 257(4):301-308. PubMed ID: 35598974
[TBL] [Abstract][Full Text] [Related]
7. Blood Biomarkers for Monitoring and Prognosis of Large Vessel Vasculitides.
Tombetti E; Hysa E; Mason JC; Cimmino MA; Camellino D
Curr Rheumatol Rep; 2021 Feb; 23(3):17. PubMed ID: 33569633
[TBL] [Abstract][Full Text] [Related]
8. Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis.
Serada S; Fujimoto M; Terabe F; Iijima H; Shinzaki S; Matsuzaki S; Ohkawara T; Nezu R; Nakajima S; Kobayashi T; Plevy SE; Takehara T; Naka T
Inflamm Bowel Dis; 2012 Nov; 18(11):2169-79. PubMed ID: 22374925
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease.
Yoshimura T; Mitsuyama K; Sakemi R; Takedatsu H; Yoshioka S; Kuwaki K; Mori A; Fukunaga S; Araki T; Morita M; Tsuruta K; Yamasaki H; Torimura T
Mediators Inflamm; 2021; 2021():8825374. PubMed ID: 33623482
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of serum leucine-rich alpha-2 glycoprotein as a disease activity biomarker in patients with rheumatoid arthritis.
Ha YJ; Kang EJ; Lee SW; Lee SK; Park YB; Song JS; Choi ST
J Korean Med Sci; 2014 Sep; 29(9):1199-204. PubMed ID: 25246736
[TBL] [Abstract][Full Text] [Related]
11. The evaluation of salivary leucine-rich alpha-2 glycoprotein (LRG) and C-reactive protein (CRP) in humans with periodontal health or periodontal disease.
Özer E; Yilmaz HE; Narin F; Sağlam M
J Periodontal Res; 2024 Apr; 59(2):387-394. PubMed ID: 38126217
[TBL] [Abstract][Full Text] [Related]
12. Clinical features and radiological findings in large vessel vasculitis: are Takayasu arteritis and giant cell arteritis 2 different diseases or a single entity?
Furuta S; Cousins C; Chaudhry A; Jayne D
J Rheumatol; 2015 Feb; 42(2):300-8. PubMed ID: 25399386
[TBL] [Abstract][Full Text] [Related]
13. Serum leucine-rich α2 glycoprotein as a potential biomarker for systemic inflammation in Parkinson's disease.
Ohmichi T; Kasai T; Shinomoto M; Kitani-Morii F; Fujino Y; Menjo K; Mizuno T
PLoS One; 2023; 18(2):e0282153. PubMed ID: 36812242
[TBL] [Abstract][Full Text] [Related]
14. Serum leucine-rich α2-glycoprotein is a useful biomarker for monitoring disease activity in patients with adult-onset Still's disease.
Ha YJ; Kang EJ; Lee SW; Park YB; Lee SK; Song JS; Choi ST
Scand J Rheumatol; 2015; 44(5):399-403. PubMed ID: 26079682
[TBL] [Abstract][Full Text] [Related]
15. ELISA for human serum leucine-rich alpha-2-glycoprotein-1 employing cytochrome c as the capturing ligand.
Weivoda S; Andersen JD; Skogen A; Schlievert PM; Fontana D; Schacker T; Tuite P; Dubinsky JM; Jemmerson R
J Immunol Methods; 2008 Jul; 336(1):22-9. PubMed ID: 18436231
[TBL] [Abstract][Full Text] [Related]
16. Leucine-rich alpha 2 glycoprotein is a new marker for active disease of tuberculosis.
Fujimoto M; Matsumoto T; Serada S; Tsujimura Y; Hashimoto S; Yasutomi Y; Naka T
Sci Rep; 2020 Feb; 10(1):3384. PubMed ID: 32099022
[TBL] [Abstract][Full Text] [Related]
17. Serum leucine-rich alpha-2 glycoprotein as a predictive factor of endoscopic remission in Crohn's disease.
Abe I; Shiga H; Chiba H; Miyazawa T; Oomori S; Shimoyama Y; Moroi R; Kuroha M; Kakuta Y; Kinouchi Y; Masamune A
J Gastroenterol Hepatol; 2022 Sep; 37(9):1741-1748. PubMed ID: 35641439
[TBL] [Abstract][Full Text] [Related]
18. Accuracy of Serum Leucine-Rich Alpha-2 Glycoprotein in Evaluating Endoscopic Disease Activity in Crohn's Disease.
Kawamura T; Yamamura T; Nakamura M; Maeda K; Sawada T; Ishikawa E; Iida T; Mizutani Y; Ishikawa T; Kakushima N; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M
Inflamm Bowel Dis; 2023 Feb; 29(2):245-253. PubMed ID: 35436345
[TBL] [Abstract][Full Text] [Related]
19. Early change in serum leucine-rich α-2-glycoprotein predicts clinical and endoscopic response in ulcerative colitis.
Karashima R; Sagami S; Yamana Y; Maeda M; Hojo A; Miyatani Y; Nakano M; Matsuda T; Hibi T; Kobayashi T
Intest Res; 2024 Jun; ():. PubMed ID: 38835140
[TBL] [Abstract][Full Text] [Related]
20. Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study.
Shinzaki S; Matsuoka K; Tanaka H; Takeshima F; Kato S; Torisu T; Ohta Y; Watanabe K; Nakamura S; Yoshimura N; Kobayashi T; Shiotani A; Hirai F; Hiraoka S; Watanabe M; Matsuura M; Nishimoto S; Mizuno S; Iijima H; Takehara T; Naka T; Kanai T; Matsumoto T
J Gastroenterol; 2021 Jun; 56(6):560-569. PubMed ID: 33942166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
